VNDA at a glance
Vanda Pharmaceuticals Inc. (VNDA, SEC CIK 1347178) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Vanda Pharmaceuticals Inc. (VNDA) shares worth $152.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Duncan Charles Cliff on November 5, 2026 of 5,803 shares at $3.80 per share.
- In the last 90 days, VNDA insiders reported 3 open-market purchases ($38K) and 0 open-market sales ($0) on Form 4, a net purchase of $38K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $216.1M
- +8.7% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$38K
- 13F holders
- 25 funds
- $152.3M · +0 vs prior quarter
- Latest 8-K
- Nov 20, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $69.8M, up 24% YoY from $56.3M
- Fanapt best performer, sales $38.8M, up 24% YoY; NEREUS $1.6M launch revenue
- Gross margin 94.0% vs 94.7% YoY, based on revenue and cost of goods sold
- Cash, equivalents and securities $140.5M vs $263.8M; operating cash outflow nine months $109.7M
- Outlook: BYSANTI launch expected Q4 2026; HETLIOZ sales may decline significantly amid generic competition
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward business risk: factors could materially adversely affect operations, financial condition, and common-stock price
- Filing identifies no newly triggered regulatory, legal, operational, competitive, market, or financial risk changes
AI summary of the VNDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension
- MSN licensed to launch its generic in Q1 2040, subject to earlier-entry exceptions
Item EX-99.1: Item EX-99.1
- Q3 revenue $69.8M, up 24% YoY, led by Fanapt $38.8M and HETLIOZ $21.7M including $7.0M of timing-related shipments
- Operating expenses $93.3M, down 18% sequentially, supporting management’s expectation for further cost reductions
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results covered quarter ended September 30, 2026
- Earnings call and press release issued October 28, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $50.5M, down 4%; Fanapt sales rose 23% to $36.0M, offset by HETLIOZ decline
- Net loss widened to $62.5M, or $1.04 per share, from $27.2M as R&D and launch spending increased
Item 2.02: Results of Operations and Financial Condition
- Vanda announced quarterly results for the period ended June 30, 2026
- Earnings call and accompanying press release dated August 5, 2026
AI summaries of VNDA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VNDA
Don't miss the next VNDA filing
- Alerts as it files. A push when VNDA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VNDA, by share count.
- Ask anything. An AI agent that reads every VNDA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Duncan Charles Cliff | Buy | Nov 5, 2026 | 5,803 | $3.80 |
| Duncan Charles Cliff | Buy | Nov 4, 2026 | 3,447 | $3.82 |
| Duncan Charles Cliff | Buy | Nov 3, 2026 | 750 | $3.80 |
| DUGAN RICHARD W | A | Jun 4, 2026 | 41,600 | - |
| Honore Tage | A | Jun 4, 2026 | 41,600 | - |
| Mitchell Stephen Ray | A | Jun 4, 2026 | 41,600 | - |
| McGuire Daniel Patrick | A | Jun 4, 2026 | 80,000 | - |
| Ward Anne Sempowski | A | Jun 4, 2026 | 41,600 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $198.8M | $216.1M |
| Operating Income | - | -$40.7M | -$151.2M |
| Net Income | $2.5M | -$18.9M | -$220.5M |
| Op. Margin | - | -20.5% | -70.0% |
| Net Margin | - | -9.5% | -102.0% |
| Balance Sheet | |||
| Total Assets | - | $656.2M | $488.9M |
| Equity | $544.9M | $538.5M | $327.2M |
| ROE | 0.5% | -3.5% | -67.4% |
| Per Share | |||
| EPS | $0.04 | $-0.33 | $-3.74 |
| Cash Flow | |||
| Operating CF | $12.8M | -$15.8M | -$109.4M |
| CapEx | - | $490K | $998K |
Source: XBRL data in Vanda Pharmaceuticals Inc. (VNDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VNDA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $152.3M |
| Q2 2026 | 25 | $188.1M |
| Q1 2026 | 24 | $192.8M |
| Q4 2025 | 23 | $216.5M |
| Q3 2025 | 24 | $139.7M |
| Q2 2025 | 26 | $135.5M |
| Q1 2025 | 23 | $81.8M |
| Q4 2024 | 19 | $70.9M |
- Millennium Management+2.66M (+166%)
- BlackRock+812.4K (+11%)
- Morgan Stanley+67.1K (+14%)
- Goldman Sachs Group+27.4K (+3%)
- Dimensional Fund Advisors+21.6K (+1%)
- AQR Capital Management−1.40M (-40%)
- Citadel Advisors LLC−684.3K (-90%)
- State Street Corp−505.9K (-14%)
- Vanguard Portfolio Management LLC−235.6K (-21%)
- Renaissance Technologies LLC−132.9K (-4%)
- D.E. Shaw & Co+33.4K
- U.S. Bancorp+547
- FMR LLC (Fidelity)−87.5K
- Prudential Financial−17.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VNDA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 20, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| SC 13G | Aug 19, 2026 | - | - | |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VNDA SEC filings: frequently asked questions
Are VNDA insiders buying or selling?
In the last 90 days, Vanda Pharmaceuticals Inc. (VNDA) officers, directors and 10% owners reported 3 open-market purchases worth $38,094 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VNDA stock?
As of September 30, 2026, the largest Vanda Pharmaceuticals Inc. (VNDA) holders among the 13F filers tracked by SignalX were BlackRock ($41.6 million), Millennium Management ($20.9 million), Renaissance Technologies LLC ($16.2 million), State Street Corp ($14.8 million), Vanguard Capital Management LLC ($12.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VNDA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Vanda Pharmaceuticals Inc. (VNDA) reported revenue of $216.1 million (up 8.7% from FY2024) and a net loss of $220.5 million. Diluted EPS was -$3.74. The figures come from the XBRL data in the 10-K.
What did VNDA report in its latest 8-K?
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension.
What are the latest VNDA SEC filings?
Vanda Pharmaceuticals Inc. (VNDA) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 5, 2026.
What is VNDA's SEC CIK number?
Vanda Pharmaceuticals Inc. (VNDA)'s SEC Central Index Key (CIK) is 1347178. EDGAR lists every VNDA filing under that number.
Ask anything about VNDA
The research agent reads VNDA's filings, financials, insider trades and 13F holders, then answers with sources.